GlassScriptPhysician profile
Larry Steven Hahn
NPI 1619911609
$8,155.21
in general payments reported to CMS, 2019-2025
33 companies · $953 in 2025
The $953 reported for 2025 was more than what 83% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,209 · 2020: $175 · 2021: $778 · 2022: $1,090 · 2023: $888 · 2024: $1,062 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,688.97 | 2019-2025 | Spravato |
| Abbvie INC. | $640.28 | 2019-2025 | |
| Pfizer INC. | $627.06 | 2019-2025 | |
| Novo Nordisk INC | $575.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $485.95 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $356.61 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $353.22 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $265.29 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.74 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $236.78 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $219.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $201.64 | 2022 | |
| Merck Sharp & Dohme LLC | $135.77 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Astellas Pharma US INC | $135.21 | 2019-2024 | Veozah |
| Bausch Health US, LLC | $116.86 | 2020-2025 | Aplenzin, Wellbutrin |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $104.27 | 2021-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.27 | 2019-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $97.81 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $94.39 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $68.88 | 2022-2023 | |
| Optos, INC. | $62.76 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $43.71 | 2021-2024 | Eliquis |
| Abbott Laboratories | $42.21 | 2023 | Proclaim, Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $41.64 | 2023 | Horizant |
| Inspire Medical Systems, INC. | $41.21 | 2023-2024 | Inspire |
| Radius Health, INC. | $33.45 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.68 | 2025 | Gattex |
| Bayer Healthcare Pharmaceuticals INC. | $22.69 | 2024 | |
| Daiichi Sankyo INC. | $19.31 | 2019 | |
| Genentech USA, INC. | $18.06 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.79 | 2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.76 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.96 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.